OmniAb (OABI) Return on Capital Employed (2021 - 2026)
OmniAb (OABI) reported Return on Capital Employed of 20.43% for Q1 2026, up 282.0% year-over-year from 5.35% in Q1 2025, and up 14.39% quarter-over-quarter from 23.86% in Q4 2025.
OmniAb (OABI) Return on Capital Employed (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Return on Capital Employed data on file, last reported at 20.43% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 20.43%, up 282.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 20.43% (up 282.0% YoY), and the FY2025 annual result was 23.22%, down 100.0% from the prior year.
- Return on Capital Employed rose to 20.43% in Q1 2026 per OABI's latest filing, from 23.86% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 6.8% in Q1 2023 and troughed at 31.34% in Q3 2022.
- A 5-year average of 19.97% and a median of 23.77% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed jumped 2085 bps in 2023, then plunged 1732 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 8.78% in 2022, then slumped by 119 bps to 19.26% in 2023, then retreated by 23 bps to 23.77% in 2024, then slipped by 0 bps to 23.86% in 2025, then advanced by 14 bps to 20.43% in 2026.
- Business Quant data shows OABI's Return on Capital Employed at 20.43% in Q1 2026, 23.86% in Q4 2025, and 23.87% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | OmniAb | 294.96 Mn | 252.00 Mn | 14.41 Mn | -20.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.43% |
| Dec 31, 2025 | -23.86% |
| Sep 30, 2025 | -23.87% |
| Jun 30, 2025 | -24.53% |
| Mar 31, 2025 | -23.25% |
| Dec 31, 2024 | -23.77% |
| Sep 30, 2024 | -24.95% |
| Jun 30, 2024 | -24.30% |
| Mar 31, 2024 | -24.11% |
| Dec 31, 2023 | -19.26% |
| Sep 30, 2023 | -10.49% |
| Jun 30, 2023 | -8.77% |
| Mar 31, 2023 | -6.80% |
| Dec 31, 2022 | -8.78% |
| Sep 30, 2022 | -31.34% |
| Jun 30, 2022 | -24.53% |
| Mar 31, 2022 | -16.52% |
| Dec 31, 2021 | -14.23% |